Introduction: Plasmacytoid dendritic cell leukemia is a rare subtype of acute leukemia, which has recently been established as a distinct pathologic entity that typically follows a highly aggressive clinical course in adults. The aim of this report is to present a case of plasmacytoid dendritic cell leukemia due to its rarity and diffi culty to recognize and diagnose it. Case report: We present a case of a 67 year-old man who presented multiple subcutaneous lesions on his face, neck, chest and upper extremities with reddish-brown, brown colour. In the bone marrow aspirate 83% of the blast cells were found. Immunophenotypically the blasts were positive for CD4, CD56, CD123 (high intensity), CD36, CD22, CD10 (10.42%), CD33, HLA-DR, CD7 (9.24%), CD38 (34.8%) and negative for CD13, CD64, CD14, CD16, CD15, CD11b, CD11c, CD3, CD5, CD2, CD8, CD19, CD20, CD34. The skin biopsy showed lymphohistiocytoid infi ltration in the dermis. The patient was diagnosed with acute plasmacytoid dendritic cell leukemia and received polychemotherapy with rapid response of skin lesions and blastic infi ltration of the bone marrow. After 3 courses of polychemotherapy the cutaneous lesions reappeared and multiplied. The blast infi ltration in the bone marrow increased to 70%. A more aggressive polychemotherapy regimen was administered, but the patient presented serious complications (febrile neutropenia) and died in septic shock 8 months after the initiation of treatment.
Introduction
Plasmacytoid dendritic cell leukemia (pDCL) is a rare subtype of acute leukemia that has recently been established as a distinct pathologic entity [1] . Due to the uncertain histogenesis of this neoplasm, the name of this entity was changed several times: agranular CD4+ NK-cell leukemia, blastic NK-cell leukemia/lymphoma, agranular CD4+/ CD56+ hematodermic neoplasm [2] . Lucio et al. suggested the plasmacytoid dendritic cell origin for this neoplasm [3] . In 2005 it was classifi ed by the WHO-EORTC (Word Health Organization/European Organization for Research and Treatment of Cancer) classifi cation for cutaneous lymphomas as CD4+/CD56+ hematodermic neoplasm or early plasmacytoid dendritic cell leukemia/lymphoma [4] . In 2008 the WHO introduced the term blastic plasmacytoid dendritic cell neoplasm (BPDCN) or plasmacytoid dendritic cell leukemia [1] . Plasmacytoid dendritic cells serve as a principal source of type I interferon and are involved in a wide variety of immune functions: antiviral, antitumoral immunity, peripheral tolerance [5] .
BPDCN predominantly aff ects older adults, but pediatric cases were also described [6] . Th e male/female ratio is 3.5/1, the median age at diagnosis is 57.5/66.4 years, being lower in the case of females [7] .
Th e clinical features of BPDCN are in the majority of cases cutaneous involvement with subsequent or simultaneous extension to bone marrow and peripheral blood. Th e disease may aff ect other areas: lymph node, spleen, liver, central nervous system, tonsils, lung [8] . A minority of the cases present with fulminant leukemia and lack of skin manifestations [9] . Tumor cells show an immature, blastic appearance with a greater variability of morphologic features [10] . Th e histopathological analysis of cutaneous lesions shows a mononuclear cell infi ltration into the dermis without angiotropism that does not damage the vessels and spares the epidermis [11] .
Th e diagnosis of pDCL is based on the immunophenotype of the tumor cells: CD4+, CD56+, lineage negative (intracytoplasmic MPO-, CD3-, CD79a-), CD11c-, CD116 low, CD123 ++high, CD36+, HLA-DR+, CD34, CD45 low [12] . Despite the apparently indolent clinical presentation and initially good response to the multiagent chemotherapy, relapses are frequent, with an aggressive clinical course. Th e prognosis is poor with a median survival of 12-14 months [7, 9, 13] . At present, there is no consensus regarding the optimal treatment of pDCL [14] , long term survival can be obtained only with allogeneic stem cell transplantation during the fi rst remission [13, 15] .
Th e aim of this report is to present a case of plasmacytoid dendritic cell leukemia, due to its rarity and diffi culty to recognize and diagnose it.
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Case report
A 67-year old man presented in our Clinic with multiple cutaneous lesions on his face, neck, back, chest and upper extremities with reddish-brown and brown colour ( Figure  1 ). Upon physical examination there was no lymphadenopathy or hepatosplenomegaly.
Th e patient had associated diseases: chronic ischemic cardiopathy, atrial fi brillation, left ventricular aneurysm, NYHA III class heart failure and permanent pace-maker for AV-block. Th e routine laboratory tests, including biochemistry, liver function, renal function were within normal range, except an elevated lactate dehydrogenase value of 647 U/l. Th e blood count showed normal white blood cell count, anemia and thrombocytopenia: WBC: 6.19 × 10 9 /l, Hgb: 11.6 g/dl, Plt: 63 × 10 9 /l. Th e peripheral blood smear showed 14% blasts and the bone marrow smear 83% blasts. Morphologically the blast cells were pleomorphic with heterogeneous size. Th e nuclei were round, irregular or indented, the nucleoli were visible. Th e cytoplasm was slightly basophilic, non-granular, with heterogeneous structure, presenting vacuoles or pseupodia-like membrane expansion ( Figure 2) .
Skin biopsy demonstrated lymphohistiocytoid infi ltrate involving the dermis and subcutis, without angiotropism, but sparing the epidermis. Immunophenotyping by fl owcytometry was performed. Th e blasts were positive for CD4, CD56, CD123 (high), CD36, HLA-DR, CD33, CD22, CD10 (10.42%), CD7 (9.24%), CD3 (34.8%) ( Figure 3 ) and were lineage negative (intracytoplasmic MPO, CD3, CD79a), and negative for the following tested surface markers: CD64, CD14, CD16, CD13, CD15, CD11b, CD11c, CD3, CD5, CD2, CD8, CD19, CD20, CD34. Th e fi nal diagnosis was plasmacytoid dendritic cell leukemia.
Given the associated cardiac diseases and permanent pace-maker, the patient was treated with a less aggressive polychemotherapy (PCT) with Vincristine, Alkeran, Methylprednisolonum. For thrombocytopenia we used supportive treatment with platelet transfusion. Th e patient obtained a rapid response of the skin lesions, in the peripheral blood there were no blasts and the tumor cell infi ltration decreased in the bone marrow to 10%. After the PCT the patient developed complications: prolonged febrile neutropenia and thrombocytopenia (WBC: 0.7 × 10 9 /l, Hgb: 9.9 g/dl, Plt: 41 × 10 9 /l) which was treated with granulocyte colony stimulating factor (G-CSF), antibiotics and platelet transfusion. After 3 courses of PCT the cutaneous lesions reappeared and multiplied. WBC: 4.83 × 10 9 /l, Hgb: 12.8 g/dl, Plt: 23 × 10 9 /l. Th e blast infi ltration in the bone marrow increased to 70%. We administered a more aggressive PCT regimen, 2 courses with Methothrexate and CHOP (Cyclophosphamide, Hydroxidaunorubicine, Vincristine, Prednisone) without anthra- cycline, adapted to the cardiac disease of the patient. But the patient had serious complications: febrile neutropenia and he died in septic shock 8 months after the initiation of PCT.
Discussion
Plasmacytoid dendritic cell leukemia (pDCL) is a rare entity that comprises less than 1% of all acute leukemias [8] , in our laboratory from a total of 237 acute leukemias diagnosed by fl owcytometry only 1 was identifi ed as pDCL (0.42%).
pDCL was characterized initially by the co-expression of CD4+ and CD56+ without expression of B-, T-lymphoid, NK-cell or myeloid lineage. However, pDCL can express markers from a diff erent lineage due to aberrant marker expression -a frequent feature of leukemic cells, or due to the fact that dendritic cells can change their morphology, phenotype and functionality depending on their diff erentiation and/or activation state [16] .
Th e clinical diff erential diagnosis in this patient included acute myeloblastic or lymphoblastic leukemia with cutaneous infi ltrates and NK/T-cell lymphoma. In our patient the blast cells show the immunophenotypic profi le described for pDCL: CD4+, CD56+, lin-, CD123 ++high, CD11c-, CD36+, HLA-DR+, CD34-, CD45 low [12] , except CD116 that was not determined in our case. Th e diagnosis of pDCL by fl owcytometry can be diffi cult when blast cells express additional markers and do not fi t completely the pDCL profi le. Th e particularity of this case was the presence of other lineage markers: myeloid: CD33, T-lymphoid: CD7, B-lymphoid: CD22, CD10. Some acute myeloblastic and lymphoblastic leukemias may express CD4 and CD56, but other lineage specifi c markers are used for diagnosis. Th e EGIL (European Group for the Immunological Characterization of Leukemias) score was < 2 for myeloid lineage and also for lymphoid lineage, so we excluded myeloblastic or lymphoblastic leukemia. Th is system is based on the number and degree of specifi city of the markers (lymphoid and myeloid) expressed by the leukemic cells [17] . Co-expression of CD33, CD2, CD7, CD117, CD22 in pDCL is acceptable and was previously described in several cases [2, 16, 18] . A number of acute leukemia cases expressed CD123, but pDCL cells express higher levels of CD123 compared to other acute leukemia cells. Nevertheless, the high expression of CD123 is a strong argument in favour of a pDC origin [12] .
Mixed myeloblastic/NK-leukemia co-express CD7, CD33 and CD56 marker that correspond to the myeloid and NK-cell precursor. In all reported cases CD4+ and CD36+ were not expressed, but other myeloid markers: CD13, MPO, CD11b were. CD34 was always expressed, which excludes pDCL [2] .
NK/T-lymphoma are diff erentiated by the presence of azurophilic granules in the cytoplasm. Expression of CD56, CD2 can be common in NK/T-lymphoma and pDCL but NK/T-lymphoma do not express CD4 [19] . Th is type of lymphoma is characterized histopathologically by angiotropism and destruction that was not described in our case.
Th e typical skin lesions, the morphology, the specifi c immunophenotypic profi le of the blast cells facilitate the pDCL diagnosis.
Th e evolution of the disease was similar as described in literature [7, 9, 13, 14, 15] . Despite of a good response to initial treatment, early relapse occurred with aggressive progression of the disease and the patient died 8 months after the initiation of PCT.
Conclusions
Plasmacytoid dendritic cell leukemia (pDCL) is a rare hematological neoplasm.
Immunophenotyping of blasts cells is indispensable in the diagnosis of pDCL. Th e CD4+, CD56+, lin-, CD123++ high, CD11c-, CD36+, HLA-DR+, CD34-, CD45 low profi le is highly suggestive for pDCL.
Th e outcome of pDCL is poor. Despite the high rate of initial response to treatment, early relapse occurs and the patients die of disease progression.
For older patients the optimal approach for pDCL therapy is unknown. Th us, it is important to elucidate the origin of the neoplastic cells for determination of the appropriate therapy.
